Please login to the form below

Not currently logged in
Email:
Password:

Onyx Pharma appoints John Osborn SVP global corporate affairs

Joins from Dendreon to lead public and government affairs activities

Dendreon's John Osborn has joined Onyx Pharmaceuticals as senior VP, global corporate affairs.

In his new role at the US-based biopharma, he will lead the company's public and government affairs activities, as well as key stakeholder relationships.

Osborn's most recent position was executive VP, general counsel and secretary at Dendreon, which markets cancer vaccine Provenge.

Prior to his time at Dendreon, he held similar roles at US Oncology and Cephalon.

He also spent time serving with the US Department of State and was a member of the bipartisan United States Advisory Commission on Public Diplomacy in 2008.

“As a lawyer, policy advocate and former diplomat, John brings a diverse and extensive background to Onyx, with broad experience across the life sciences industry and the US government,” said Dr Anthony Coles, president and CEO of Onyx.

“John is a proven leader and his unique expertise aligns well with our plan for global growth as a multi-product company reaching patients around the world.”

20th July 2012

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Senior Brand Manager - Harlow
Competitive
Sales Manager - Media Publishing – Cheshire
25,000 to 35,000 per annum
UK Marketing Director
80,000 to 100,000 per annum
Group Account Director –Healthcare Advertising
Neg

Subscribe to our email news alerts

PMHub

Add my company
Networks in Health

Networks in Health is the unique global alliance of trusted online physician networks founded and operated by Doctors.net.uk....

Latest intelligence

Clinical trial regulation in Mexico
Regulatory improvements make Mexico an appealing destination for clinical trials outsourcing...
Online Physician Communities
How can pharma deliver returns on increased digital investment?
Independent online professional networks work best as part of a multi-channel campaign  ...
The impact of Hollande's healthcare reforms in France
A tougher environment for pharma, with market access and regulatory challenges...